The future of inflammatory bowel disease care.
Sandborn, William J
The future of inflammatory bowel disease care. [electronic resource] - Reviews in gastroenterological disorders 2009 - E69-77 p. digital
Publication Type: Journal Article; Review
1949-4386
Adalimumab
Adrenal Cortex Hormones--therapeutic use
Anti-Inflammatory Agents, Non-Steroidal--therapeutic use
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Azathioprine--therapeutic use
Certolizumab Pegol
Clinical Trials as Topic
Gastrointestinal Agents--therapeutic use
Humans
Immunoglobulin Fab Fragments--therapeutic use
Immunosuppressive Agents--therapeutic use
Inflammatory Bowel Diseases--drug therapy
Infliximab
Mercaptopurine--therapeutic use
Mesalamine--therapeutic use
Natalizumab
Polyethylene Glycols--therapeutic use
Tumor Necrosis Factor-alpha--antagonists & inhibitors
The future of inflammatory bowel disease care. [electronic resource] - Reviews in gastroenterological disorders 2009 - E69-77 p. digital
Publication Type: Journal Article; Review
1949-4386
Adalimumab
Adrenal Cortex Hormones--therapeutic use
Anti-Inflammatory Agents, Non-Steroidal--therapeutic use
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Azathioprine--therapeutic use
Certolizumab Pegol
Clinical Trials as Topic
Gastrointestinal Agents--therapeutic use
Humans
Immunoglobulin Fab Fragments--therapeutic use
Immunosuppressive Agents--therapeutic use
Inflammatory Bowel Diseases--drug therapy
Infliximab
Mercaptopurine--therapeutic use
Mesalamine--therapeutic use
Natalizumab
Polyethylene Glycols--therapeutic use
Tumor Necrosis Factor-alpha--antagonists & inhibitors